Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia

Indian Journal of Gastroenterology

Volumn 23, Issue 4, 2004, Pages 131-134

  Hatzitolios, Apostolos ^a   Savopoulos, Christos ^a   Lazaraki, Georgia ^a   Sidiropoulos, Ioannis ^a   Haritanti, Persefoni ^a   Lefkopoulos, Anastasios ^a   Karagiannopoulou, Georgia ^a   Tzioufa, Valentini ^a   Dimitrios, Koliouskas ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Non alcoholic steatohepatitis

Indexed keywords

AMINOTRANSFERASE; ANTILIPEMIC AGENT; ATORVASTATIN; FISH OIL; LIPID; OMEGA 3 FATTY ACID; TETRAHYDROLIPSTATIN;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; ECHOGRAPHY; FATTY LIVER; FEMALE; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; OBESITY; TREATMENT OUTCOME;

ADULT; AGED; CHI-SQUARE DISTRIBUTION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FATTY ACIDS, OMEGA-3; FATTY LIVER; FEMALE; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HUMANS; HYPERLIPIDEMIAS; LACTONES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRROLES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 4344593276     PISSN: 02548860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Powell EE, Cooksley WGE, Hansen R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of 42 patients for up to 21 years. Hepatology 1990;11:74-80.
2. Ballentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F, et al. Prevalence and risk factors for hepatic steatosis in northern Italy. Ann Intern Med 2000;132:112-7.
3. Weltman MD, Farrell GC, Hall P, Ingelman-Sundberg M, Liddle C. Hepatocyte cytochrome P450 2E1 is increased in patients with non-alcoholic steatohepatitis. Hepatology 1998;27:128-33.
4. James OFW, Day CP. Nonalcoholic steatohepatitis (NASH): a disease of emerging identity and importance. J Hepatol 1998;29:495-501.
5. Teli M, James OF, Burt AD, Benett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow up study. Hepatology 1995;22:1714-7.
6. Angulo P, Lindor KD. Treatment of nonlacoholic fatty liver: present and emerging therapies. Semin Liver Dis 2001;21:81-8.
7. Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990;99:1408-13.
8. Andersen T, Gluud C, Franzmann MB, Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese patients. J Hepatol 1991;12:224-9.
9. Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol 1999;31:384.
10. Ceriani R, Bunati S, Morini L, Sacchi E, Colombo G. Effect of ursodeoxycholic acid plus diet in patients with non-alcoholic steatohepatitis (Abstract). Hepatology 1998;28:386A.
11. Gulbahar O, Karasu ZA, Ersoz G, Akarca US, Musoglu A. Treatment of nonalcoholic steatohepatitis with N-acetylcysteine (Abstract). Gastroenterology 2000;118:A1444.
12. Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatrics 2000;136:734-8.
13. Jaeschke H, Wang Y, Essani NA. Reactive oxygen species activate the transcription factor NF-kB in the liver by induction of lipid peroxidation (Abstract). Hepatology 1996;24:238A.
14. Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, et al. Ursodeoxycholic acid or clofibrate in the treatment of nonalcoholic-induced steatohepatitis: a pilot study. Hepatology 1996;23:1464-7.
15. Willett WC, Dietz WH, Colditz GA. Guidelines for healthy weight. N Engl J Med 1999;341:427-34.
16. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Non alcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-74.
17. Katen MB, Zock PL, Mensink RP. Effects of fats and fatty acids on blood lipids in humans: an overview. Am J Clin Nutr 1994;60(Suppl):1017S-1022S.
18. Roth BD. The discovery and development of atorvastatine, a potent novel hypolipidemic agent. Prop Med Chem 2002;40:1-22.
19. Lucas CP, Boldrin MN, Reaven GM. Effect of orlistat added to diet (30% of calories from fat) on plasma lipids, glucose and insulin in obese patients with hypercholesterolemia. Am J Cardiol 2003;91:961-4.
20. Angulo P, Lindor KD. Insulin resistance and mitochondrial abnormalities in NASH: a cool look into a burning issue. Gastroenterology 2001;120:1281-5.
21. Ueno T, Sugawara H, Sujaku K, Hashimoto O, Tsuji R, Tamaki S, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997;27:103-7.
22. Saverymuttu SH, Joseph AE, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J (Clin Res Ed) 1986;292:13-5.
23. Mendler MH, Bouillet P, Le Sidaner A, Lavoine E, Labrousse F, Sautereau D, et al. Dual energy CT in the diagnosis and quantification of fatty liver: limited clinical value in comparison to ultrasound scan and single-energy CT, with special reference to iron overload. J Hepatol 1998;28:785-94.
24. Fishbein M, Stevens RW. Rapid MRI using a modified Dixon technique: a non-invasive and effective method for detection and monitoring of fatty metamorphosis of the liver. Pediatr Radiol 2001;31:806-9.